Mark Fladrich appointed Chair of QBiotics
BRISBANE, 7 November 2024
QBiotics Group Limited (QBiotics) announces that Mark Fladrich has been appointed to the role of Non-executive Chair.
CEO and Managing Director, Stephen Doyle commented, “We are grateful to Mark for stepping into the Chair role, following the recent passing of our former Chair, Sue Foden. Mark's extensive industry experience and commitment to our vision make him well-suited for leading the company, moving forward, building upon the strong legacy that Sue has left behind.”
Mark joined QBiotics as Non-executive Director on 20 May 2024. He is an experienced pharmaceutical executive with more than 30 years of experience in the industry, including 23 years with AstraZeneca. Mark brings to QBiotics a wealth of knowledge and experience in global commercial strategy and implementation across all phases of the pharmaceutical product lifecycle and across many geographies. Mark held various senior roles during his time with AstraZeneca including Vice President Global Strategic Marketing, Country President roles in Germany, Australia and New Zealand and Regional Head of Southern and Western Europe. Prior to joining the Board of QBiotics he was the Chief Commercial Officer of Grunenthal - a privately owned German company specialising in pain management.
—ends—
FURTHER INFORMATION
STEPHEN DOYLE, CEO & MANAGING DIRECTOR
communications@qbiotics.com or
MEDIA ENQUIRIES / NOTES FOR EDITORS
JANE LOWE, IR DEPARTMENT
jane.lowe@irdepartment.com.au +61 411 117 774
ABOUT QBIOTICS
QBiotics is an unlisted public Australian life sciences company that specialises in the discovery and development of novel cell signalling small molecules. QBiotics applies phenotypic screening to generate breakthrough innovation in the discovery of first in class solutions to challenging medical conditions. Our current clinical focus is on novel treatments for cancer and debilitating chronic wounds.
QBiotics’ lead oncology drug, tigilanol tiglate, is a small molecule targeting a range of solid tumours and is currently in human clinical Phase II development. A veterinary formulation of tigilanol tiglate is registered and marketed as an oncology pharmaceutical, under the trade name STELFONTA®, in the USA, Europe, the UK and Australia.
QBiotics’ lead wound healing drug candidate, EBC 1013 is a small molecule targeting a range of wounds including chronic and acute wounds and burns. A first-in-human Phase I clinical development in patients with venous leg ulcers is open for recruitment.